These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 9622543

  • 21. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
    Tait BD, Hagen S, Domagala J, Ellsworth EL, Gajda C, Hamilton HW, Prasad JV, Ferguson D, Graham N, Hupe D, Nouhan C, Tummino PJ, Humblet C, Lunney EA, Pavlovsky A, Rubin J, Gracheck SJ, Baldwin ET, Bhat TN, Erickson JW, Gulnik SV, Liu B.
    J Med Chem; 1997 Nov 07; 40(23):3781-92. PubMed ID: 9371244
    [Abstract] [Full Text] [Related]

  • 22. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V, Burello E, Miertus S.
    Bioorg Med Chem; 2005 Sep 15; 13(18):5492-501. PubMed ID: 16054372
    [Abstract] [Full Text] [Related]

  • 23. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J, Wallberg H, Vrang L, Oscarson S, Parkes K, Hallberg A, Samuelsson B.
    Eur J Med Chem; 2010 Jan 15; 45(1):160-70. PubMed ID: 19926360
    [Abstract] [Full Text] [Related]

  • 24. Nonpeptidic potent HIV-1 protease inhibitors.
    Prasad JV, Lunney EA, Para KS, Tummino PJ, Ferguson D, Hupe D, Domagala JM, Erickson JW.
    Drug Des Discov; 1996 Apr 15; 13(3-4):15-28. PubMed ID: 8874041
    [Abstract] [Full Text] [Related]

  • 25. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors.
    Jia ZJ, Wu Y, Huang W, Zhang P, Song Y, Woolfrey J, Sinha U, Arfsten AE, Edwards ST, Hutchaleelaha A, Hollennbach SJ, Lambing JL, Scarborough RM, Zhu BY.
    Bioorg Med Chem Lett; 2004 Mar 08; 14(5):1229-34. PubMed ID: 14980671
    [Abstract] [Full Text] [Related]

  • 26. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
    Rusere LN, Lockbaum GJ, Lee SK, Henes M, Kosovrasti K, Spielvogel E, Nalivaika EA, Swanstrom R, Yilmaz NK, Schiffer CA, Ali A.
    J Med Chem; 2019 Sep 12; 62(17):8062-8079. PubMed ID: 31386368
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN, Shepherd TA, Baxter AJ, Burgess J, Hatch SD, Lubbehusen P, Wiskerchen M, Muesing MA.
    J Med Chem; 1996 Jan 05; 39(1):96-108. PubMed ID: 8568831
    [Abstract] [Full Text] [Related]

  • 30. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
    Kazmierski WM, Andrews W, Furfine E, Spaltenstein A, Wright L.
    Bioorg Med Chem Lett; 2004 Nov 15; 14(22):5689-92. PubMed ID: 15482949
    [Abstract] [Full Text] [Related]

  • 31. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
    Shen DM, Shu M, Willoughby CA, Shah S, Lynch CL, Hale JJ, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Lyons K, Pivnichny JV, Kwei GY, Carella A, Carver G, Holmes K, Schleif WA, Danzeisen R, Hazuda D, Kessler J, Lineberger J, Miller MD, Emini EA.
    Bioorg Med Chem Lett; 2004 Feb 23; 14(4):941-5. PubMed ID: 15012998
    [Abstract] [Full Text] [Related]

  • 32. P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.
    Degoey DA, Grampovnik DJ, Chen HJ, Flosi WJ, Klein LL, Dekhtyar T, Stoll V, Mamo M, Molla A, Kempf DJ.
    J Med Chem; 2011 Oct 27; 54(20):7094-104. PubMed ID: 21899332
    [Abstract] [Full Text] [Related]

  • 33. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J, Bonham NM, Nillroth U, Hansson T, Zuccarello G, Bouzide A, Aqvist J, Classon B, Danielson UH, Karlén A, Kvarnström I, Samuelsson B, Hallberg A.
    J Med Chem; 1997 Mar 14; 40(6):885-97. PubMed ID: 9083477
    [Abstract] [Full Text] [Related]

  • 34. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
    Surleraux DL, Tahri A, Verschueren WG, Pille GM, de Kock HA, Jonckers TH, Peeters A, De Meyer S, Azijn H, Pauwels R, de Bethune MP, King NM, Prabu-Jeyabalan M, Schiffer CA, Wigerinck PB.
    J Med Chem; 2005 Mar 24; 48(6):1813-22. PubMed ID: 15771427
    [Abstract] [Full Text] [Related]

  • 35. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
    Skulnick HI, Johnson PD, Aristoff PA, Morris JK, Lovasz KD, Howe WJ, Watenpaugh KD, Janakiraman MN, Anderson DJ, Reischer RJ, Schwartz TM, Banitt LS, Tomich PK, Lynn JC, Horng MM, Chong KT, Hinshaw RR, Dolak LA, Seest EP, Schwende FJ, Rush BD, Howard GM, Toth LN, Wilkinson KR, Romines KR.
    J Med Chem; 1997 Mar 28; 40(7):1149-64. PubMed ID: 9089336
    [Abstract] [Full Text] [Related]

  • 36. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.
    Bold G, Fässler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, Rösel J, Stover D, Tintelnot-Blomley M, Acemoglu F, Beck W, Boss E, Eschbach M, Hürlimann T, Masso E, Roussel S, Ucci-Stoll K, Wyss D, Lang M.
    J Med Chem; 1998 Aug 27; 41(18):3387-401. PubMed ID: 9719591
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
    Wilkerson WW, Dax S, Cheatham WW.
    J Med Chem; 1997 Dec 05; 40(25):4079-88. PubMed ID: 9406598
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
    Pruitt JR, Pinto DJ, Galemmo RA, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H, Smallwood A, Wong PC, Wright MR, Bai S, Luettgen JM, Knabb RM, Lam PY, Wexler RR.
    J Med Chem; 2003 Dec 04; 46(25):5298-315. PubMed ID: 14640539
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.